Similar articles

• An in vivo system in man for quantitation of estrogenicity. II. Pharmacologic changes in binding capacity of serum corticosteroid-binding globulin induced by conjugated estrogens, mestranol, and ethinyl estradiol.

  Moore DE, Kawagoe S, Davajan V, Nakamura RM, Mishell DR. Moore DE, et al. Am J Obstet Gynecol. 1978 Feb 15;130(4):482-6. Am J Obstet Gynecol. 1978. PMID: 204191 No abstract available.
• Conjugated estrogens and hypercoagulability.

  von Kaulla E, Droegemueller W, von Kaulla KN. von Kaulla E, et al. Am J Obstet Gynecol. 1975 Jul 15;122(6):688-92. doi: 10.1016/0002-9378(75)90572-4. Am J Obstet Gynecol. 1975. PMID: 168774
• Massive hyperlipemia during estrogen therapy.

  Molitch ME, Oill P, Odell WD. Molitch ME, et al. JAMA. 1974 Feb 4;227(5):522-5. JAMA. 1974. PMID: 4358883 No abstract available.
• Oral contraceptives and thromboembolism.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 1972 Aug 18;14(17):61-2. Med Lett Drugs Ther. 1972. PMID: 4567564 Review. No abstract available.
• New aspects of the thrombogenic effect of oral contraceptives.

  Astedt B. Astedt B. Am Heart J. 1975 Jul;90(1):1-3. doi: 10.1016/0002-8703(75)90249-5. Am Heart J. 1975. PMID: 1094817 Review. No abstract available.